ELDN Eledon Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1404281 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.6%
TTM EPS YoY-586.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-257.1%
ROA-71.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets34.5%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $66.27M | $51.96M | $30.31M | $27.08M | $23.73M |
| SG&A expense | $16.98M | $18.61M | $12.69M | $12.70M | $13.13M |
| Operating income | — | — | -$43.00M | -$88.43M | -$36.87M |
| Pretax income | -$45.58M | -$35.75M | -$116.54M | -$87.97M | -$36.86M |
| Income tax | $35,000 | $431,000 | $0 | $0 | -$2.35M |
| Net income | -$45.62M | -$36.18M | -$116.54M | -$87.97M | -$34.51M |
| EPS (basic) | -0.52 | -0.66 | -4.73 | -6.16 | -2.33 |
| EPS (diluted) | -0.52 | -0.66 | -4.73 | -6.16 | -2.33 |
| Weighted avg. shares (diluted) | 81.84M | 48.54M | 24.62M | 14.29M | 14.82M |
| Balance sheet | |||||
| Cash & equivalents | $22.81M | $20.55M | $4.61M | $56.41M | $84.83M |
| Short-term investments | $110.53M | $119.63M | $46.49M | $0 | — |
| Current assets | $135.69M | $143.73M | $56.13M | $59.52M | $88.35M |
| Goodwill | — | — | $0 | $0 | $48.65M |
| Total assets | $169.01M | $177.41M | $89.07M | $92.79M | $170.55M |
| Current liabilities | $18.34M | $11.58M | $3.90M | $6.47M | $4.40M |
| Total liabilities | $32.23M | $59.27M | $81.86M | $8.61M | $6.55M |
| Shareholders' equity | $81.08M | $62.45M | -$48.49M | $23.79M | $164.00M |
| Shares outstanding | 75.43M | 59.79M | 24.21M | 13.78M | 14.31M |
| Cash flow statement | |||||
| Operating cash flow | -$62.34M | -$47.27M | -$39.53M | -$28.42M | -$28.91M |
| Investing cash flow | $10.79M | -$70.31M | -$45.29M | — | — |
| Financing cash flow | $53.81M | $133.52M | $33.02M | — | -$449,000 |
| Stock-based compensation | $10.45M | $13.12M | $6.54M | $8.15M | $7.90M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.